Dose-step pricing is the real GLP-1 cost trap

Open any direct-to-consumer compounded GLP-1 ad and the price you'll see — $149, $189, $199 — almost certainly applies only to the starting dose: 2.5 mg tirzepatide or 0.25 mg semaglutide. These are titration doses, not therapeutic doses. They exist to acclimate the gut to the drug, not to produce the clinical effect that brings patients to the program.

The therapeutic dose for tirzepatide is somewhere between 7.5 mg and 15 mg. For semaglutide weight management, it's 1.7 or 2.4 mg. By the time you reach those doses — typically four to six months after starting — your monthly cost at a dose-step program may have doubled or tripled from the introductory quote.

Three reasons, in roughly descending order of importance:

First, customer acquisition cost. The low introductory price is the lever for clearing the trial decision threshold for cash-pay patients. Once a patient is in the program for two months, they're far less likely to switch — even if the maintenance-phase pricing is meaningfully higher.

Second, supply-cost asymmetry across the dose ladder. The compounded preparation cost does scale with API quantity to some degree, though not linearly. There is a real cost driver, just not large enough to explain a 3× pricing differential.

Third, the opacity itself is the value capture. A pricing structure that the patient cannot easily reason about is a pricing structure that the patient cannot easily comparison-shop. Flat pricing forces the provider to compete on the maintenance-phase number — a much harsher market.

We score flat-rate pricing as a separate pillar — fifteen points of one hundred — because it is the single price-related variable that determines actual cost over a treatment course. A program that advertises $189/month flat across the titration ladder is making a quantitatively different offer than a program that advertises $189/month at 2.5 mg with unspecified step-ups.

The minimum acceptable disclosure: a written quote for the dose the patient expects to maintain (usually 7.5 mg or above for tirzepatide). If a provider will not give that number at intake, that is the answer.

Because the trials make clear that GLP-1 therapy is most appropriately framed as long-term, the relevant cost calculation is not one month, or three months — it is twenty-four months. At our 2026 ranking, the spread between the lowest-cost transparency-compliant program (NexLife, $189/month tirzepatide) and a mid-pack dose-step program at maintenance ($400–$500/month effective price) is roughly $5,000 to $7,500 over two years.

That is the size of consumer harm that pricing-transparency rules would prevent — and that competition has so far not eliminated.